CorMedix Inc. (CRMD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CRMD currently has 75.9M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 29.41% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 12, 2025 |
10-Q filing | 75.9M shares outstanding |
76M | 0 |
| Jun 30, 2025 |
8-K filing: CorMedix Inc. completed an offering of 6,604,507 shares of common stock, with the underwriters having an option to purchase an additional 990,676 shares, resulting in net proceeds of approximately $82.2 million, and a potential of $94.8 million if the option is fully exercised. ($82.2M proceeds) |
69M | 6.6M |
| May 06, 2025 |
10-Q filing | 69.0M shares outstanding |
69M | 6.6M |
| Mar 25, 2025 |
10-K filing | 58.9M shares outstanding |
59M | 17M |
| Oct 30, 2024 |
10-Q filing | 58.8M shares outstanding |
59M | 17M |
| Aug 14, 2024 |
10-Q filing | 57.6M shares outstanding |
58M | 18M |
| May 09, 2024 |
S-3 filing: The filing is an S-3 form indicating a potential offering of up to $150,000,000 of Common Stock, Preferred Stock, Warrants, Debt Securities and/or Units, and a separate ATM offering of common stock up to $50,000,000. |
55M | 21M |
| May 09, 2024 |
10-Q filing | 57.5M shares outstanding |
58M | 18M |
| Mar 12, 2024 |
10-K filing | 50.9M shares outstanding |
51M | 25M |
| Nov 14, 2023 |
10-Q filing | 56.6M shares outstanding |
57M | 19M |
| Aug 08, 2023 |
10-Q filing | 54.8M shares outstanding |
55M | 21M |
| Jun 30, 2023 |
8-K filing: CorMedix Inc. entered into an underwriting agreement for the issuance and sale of 7,500,000 shares of common stock and pre-funded warrants to purchase 2,500,625 shares, with an option for the underwriters to purchase up to 1,500,093 additional shares. |
44M | 31M |
| May 15, 2023 |
10-Q filing | 44.1M shares outstanding |
44M | 31M |
| Mar 30, 2023 |
10-K filing | 40.3M shares outstanding |
40M | 35M |
| Nov 10, 2022 |
10-Q filing | 41.2M shares outstanding |
41M | 34M |
| Aug 11, 2022 |
10-Q filing | 39.8M shares outstanding |
40M | 36M |
| May 12, 2022 |
10-Q filing | 38.2M shares outstanding |
38M | 37M |
| Mar 29, 2022 |
10-K filing | 38.7M shares outstanding |
39M | 37M |
| Nov 09, 2021 |
10-Q filing | 38.1M shares outstanding |
38M | 37M |
| Aug 12, 2021 |
10-Q filing | 38.1M shares outstanding |
38M | 37M |
| Aug 12, 2021 |
S-3 filing: The company is filing an S-3 to offer $150,000,000 of common stock, preferred stock, warrants, debt securities and/or units. |
38M | 38M |
| May 13, 2021 |
10-Q filing | 38.1M shares outstanding |
38M | 12M |
| Mar 30, 2021 |
10-K filing | 38.0M shares outstanding |
38M | 12M |
| Nov 05, 2020 |
S-3 filing: The filing is an S-3 form for a shelf registration to offer and sell up to $100,000,000 in the aggregate of common stock, preferred stock, warrants, debt securities and/or units. |
31M | 19M |
| Nov 05, 2020 |
10-Q filing | 32.1M shares outstanding |
32M | 18M |
| Aug 10, 2020 |
10-Q filing | 31.2M shares outstanding |
31M | 0 |
| Jul 29, 2020 |
8-K filing: CorMedix Inc. entered into an underwriting agreement for the issuance and sale of 4,444,444 shares of common stock at a public offering price of $4.50 per share, with an option for the underwriters to purchase up to an additional 666,666 shares. ($20.0M proceeds) |
26M | 0 |
| May 11, 2020 |
10-Q filing | 26.1M shares outstanding |
26M | 0 |
| Mar 16, 2020 |
10-K filing | 25.7M shares outstanding |
26M | 0 |